Blocking the endocannabinoid system - Weight reduction and cardiovascular risk management;Die blockade des endocannabinoidsystems - Gewichtsreduktion und kardiovaskuläres risikomanagement

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 12, 2005, Pages 665-668

  Bramlage, Peter ^a   Bocking W ^a   Kirch, W ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (1,1 DIMETHYLHEPTYL) 2 (3 HYDROXY 7 HYDROXYMETHYLDECAHYDRO 1 NAPHTHYL)PHENOL; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; ENDOCANNABINOID; RIMONABANT;

CARDIOVASCULAR RISK; DYSLIPIDEMIA; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; ENDOCANNABINOIDS; HUMANS; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RISK FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 17144397623     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-865077     Document Type: Review

References (32)

1. RIO-EUROPE. Rimonabant impressive once more in obesity: http:// www.theheart.org 〉 Heartwire 〉 News 〉, Aug 29, 2004
2. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421
3. Two-year data for rimonabant "encouraging" once again for weight loss, CV risk factor reduction: http://www.theheart.org > Heartwire > News >, Nov 9, 2004
4. Bensaid M, Cary-Bobo M, Esclangon A et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908-914
5. Bramlage P, Wittchen HU, Pittrow D et al. Recognition and management of overweight and obesity in primary care in Germany. Int J Obes Relat Metab Disord 2004; 28: 1299-1308
6. Christopoulos A, Coles P, Lay L, Lew MJ, Angus JA. Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. Br J Pharmacol 2001; 132: 1281-1291
7. Cleland JG, Ghosh J, Freemantle N et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004; 6: 501-508
8. Cota D, Marsicano G, Lutz B et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 2003; 27: 289-301
9. Cota D, Marsicano G, Tschop M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431
10. Devane WA, Hanus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949
11. Di Marzo V, Bifulco M, De Petrocellis L The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-784
12. Di Marzo V, Goparaju SK, Wang L et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825
13. Gomez R, Navarro M, Ferrer B et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-9617
14. Guerre-Millo M. Adipose tissue hormones. J Endocrinol Invest 2002; 25: 855-861
15. Hao S, Avraham Y, Mechoulam R, Berry EM. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 2000; 392: 147-156
16. Harrold JA, Elliott JC, King PJ, Widdowson PS, Williams G. Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 2002; 952: 232-238
17. Hildebrandt AL, Kelly-Sullivan DM, Black SC. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 2003; 462: 125-132
18. Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science 2003; 299: 853-855
19. Kirkham TC, Williams CM. Endogenous cannabinoids and appetite. Nutr Res Rev 2001; 14: 65-86
20. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550-557
21. Landi M, Croci T, Rinaldi-Carmona M, Maffrand JP, Le Fur G, Manara L Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors. Eur J Pharmacol 2002; 450: 77-83
22. Lange JH, Coolen HK, van Stuivenberg HH et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J Med Chem 2004; 47: 627-643
23. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564
24. McAllister SD, Glass M. CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 161-171
25. McPartland JM, Glass M. Functional mapping of cannabinoid receptor homologs in mammals, other vertebrates, and invertebrates. Gene 2003; 312: 297-303
26. Mechoulam R. Cannabis as a therapeutic agent. Boca Raton: CRC Press, In: Mechoulam R (Editor). 1986
27. Merker N, Wagner N, Kirch W, Muller MJ. Frühzeitige Prevention von Adipositas und Herz-Kreislauferkrankungen. Dtsch Med Wochenschr 2002; 127: 2661-2663
28. Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003; 138: 24-32
29. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-180
30. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991; 40: 695-700
31. Ravinet Trillou C, Arnone M, Delgorge C et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345-353
32. Xie XQ, Pavlopoulos S, DiMeglio DM, Makriyannis A. Conformational studies on a diastereoisomeric pair of tricyclic nonclassical cannabinoids by NMR spectroscopy and computer molecular modeling. J Med Chem 1998; 41: 167-174